Citigroup Inc Akebia Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 151,405 shares of AKBA stock, worth $295,239. This represents 0.0% of its overall portfolio holdings.

Number of Shares

151,405

Previous 46,560 225.18%

Holding current value

$295,239

Previous $47,000 323.4%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.94 - $1.55 $98,554 - $162,509	104,845 Added 225.18%	151,405 $199,000
Q2 2024 Aug 12, 2024	SELL	$0.86 - $1.63 $121,487 - $230,261	-141,265 Reduced 75.21%	46,560 $47,000
Q1 2024 May 10, 2024	SELL	$1.27 - $2.24 $149,581 - $263,829	-117,781 Reduced 38.54%	187,825 $343,000
Q4 2023 Feb 09, 2024	BUY	$0.8 - $1.28 $122,295 - $195,672	152,869 Added 100.09%	305,606 $378,000
Q3 2023 Nov 09, 2023	BUY	$0.87 - $1.84 $132,838 - $280,945	152,688 Added 311608.16%	152,737 $174,000
Q1 2023 May 11, 2023	SELL	$0.56 - $1.15 $379 - $778	-677 Reduced 93.25%	49 $0
Q4 2022 Feb 09, 2023	SELL	$0.25 - $0.58 $11,474 - $26,620	-45,897 Reduced 98.44%	726 $0
Q3 2022 Nov 10, 2022	SELL	$0.3 - $0.46 $19,099 - $29,285	-63,664 Reduced 57.73%	46,623 $15,000
Q2 2022 Aug 10, 2022	SELL	$0.32 - $0.67 $40,480 - $84,757	-126,503 Reduced 53.42%	110,287 $39,000
Q1 2022 May 12, 2022	SELL	$0.72 - $2.93 $316,365 - $1.29 Million	-439,396 Reduced 64.98%	236,790 $170,000
Q4 2021 Feb 10, 2022	BUY	$2.26 - $3.34 $514,247 - $759,993	227,543 Added 50.72%	676,186 $1.53 Million
Q3 2021 Nov 10, 2021	BUY	$2.35 - $3.88 $1.05 Million - $1.74 Million	448,643 New	448,643 $1.29 Million

Others Institutions Holding AKBA

# of Institutions

120

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $359M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account